On June 24, 2025, Alaunos Therapeutics, Inc. entered into a subscription agreement to raise $850,000 by selling shares of its Series A-2 Convertible Preferred Stock, priced at $1,000 each, allowing holders a 10% annual dividend and conversion rights into common stock.